ScreenerHero

ACRV Acrivon Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · acrivon.com
1.880USD+1.08%Mkt Cap: 80.56M $P/E: —

Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generat…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap80.56M USD
Enterprise Value-8.14M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-77.91M USD
Revenue/Share—
Last Price1.880 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees74
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.13
PEG—
EV/EBITDA0.11
EV/Revenue—
P/S—
P/B0.92
EPS (TTM)-1.76
EPS (Forward)-1.64
52W Range
1.27027% of range3.560
52W High3.560 USD
52W Low1.270 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-69.24%
ROA-60.06%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-63.66M USD
CapEx (TTM)1.67M USD
FCF Margin—
FCF Yield-49.43%
Net Debt-87.84M USD
Net Debt/EBITDA1.14
Balance Sheet
Debt/Equity0.02
Current Ratio7.99
Quick Ratio7.86
Book Value/Sh2.02 USD
Cash/Share2.10 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)11.50 USD
Upside (mean)+511.7%
Target Range7.000 USD – 19.00 USD
7.000+511.7% to mean19.00
# Analysts6
Ownership
Shares Out.42.85M
Float25.83M
Insiders15.40%
Institutions50.34%
Short Interest
Short Ratio3.6d
Short % Float4.19%
Short % Out.2.81%
Shares Short1.20M
Short (prev mo.)1.24M
Technical
SMA 501.931 (-2.7%)
SMA 2001.814 (+3.6%)
Beta1.93
S&P 52W Chg16.45%
Avg Vol (30d)341.08K
Avg Vol (10d)296.70K
Technical Indicators
RSI (14)43.5
MACD-0.0007
MACD Signal0.0279
MACD Hist.-0.0285
BB Upper2.190 USD
BB Middle2.006 USD
BB Lower1.822 USD
BB Width18.39%
ATR (14)0.1279 USD
Vol Ratio (20d)0.91x